Skip to main content
OpenTrials
Completed

NCT Number: NCT05605236

Stereotactic Margins in Localized Bronchial Cancer (T1/T2a, N0)

Bronchopulmonary cancer is the first cause of mortality in the world. We want to update the margins used in stereotactic radiotherapy, in the context of localized lung cancer, of non-surgical management.

The investigators wish to redefine the stereotactic radiotherapy margins according to the histological type in localized non-small cell lung cancer.

Indeed, these criteria were previously defined on a smaller cohort, in the context of 3D radiotherapy (mainly T3, T4 tumors). In addition, the incidence of radiation pneumonitis is highly dependent on the irradiated lung volume, which in turn depends on the CTV margins used.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchial Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de chirurgie thoracique - CHU de Strasbourg - France

Strasbourg, 67091, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Major subject (≥18 years old)
  • Subject operated on at HUS for T1/T2a N0 stage lung adenocarcinoma or squamous cell carcinoma before 30/09/2019
  • CT scan available on the HUS imaging server or on CD
  • Subject who has not expressed opposition to the use of his or her data for research purposes

Exclusion criteria

  • Subject who has expressed opposition to participating in the study
  • Impossibility to give the subject informed information (difficulties in understanding the subject, ...)
  • Subject under legal protection
  • Subject under guardianship or curatorship

Treatment and study plan

Primary outcomes

  1. Retrospective histological study of tumor cell dissemination around the tumor

    Time frame: Files analysed retrospectively from January 01, 2009 to December 31, 2019 will be examined

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: Stereotactic

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Nov 4, 2022
Registry last updated
Dec 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.